Human SEMA4D _CD100 Protein Vector: HEK293
- Known as:
- Human SEMA4D _CD100 Protein Vector: HEK293
- Catalog number:
- 10098-H03H
- Product Quantity:
- 100μg
- Category:
- -
- Supplier:
- Provo
- Gene target:
- Human SEMA4D _CD100 Protein Vector: HEK293
Related genes to: Human SEMA4D _CD100 Protein Vector: HEK293
- Gene:
- SEMA4D NIH gene
- Name:
- semaphorin 4D
- Previous symbol:
- SEMAJ, C9orf164
- Synonyms:
- CD100, coll-4, FLJ39737
- Chromosome:
- 9q22.2
- Locus Type:
- gene with protein product
- Date approved:
- 1999-06-25
- Date modifiied:
- 2016-10-05
Related products to: Human SEMA4D _CD100 Protein Vector: HEK293
Related articles to: Human SEMA4D _CD100 Protein Vector: HEK293
- High-risk MYCN-amplified neuroblastoma is associated with a dire prognosis and often metastasizes to the bone marrow. However, systemic immune remodeling and its effect on the bone marrow niche remain unclear. - Source: PubMed
Publication date: 2026/09/15
Embaie Bethel TesfaiAlchahin Adele MVelentza LillyOlsen Thale KristinGavriliuc Ioana MariaMei ShenglinBaryawno Ninib - Multiple myeloma represents a systemic disease of the bone marrow (BM) niche, in which immune and skeletal pathways are tightly interconnected. However, the independent prognostic significance of bone and immune-related markers in newly diagnosed multiple myeloma (NDMM) remains incompletely understood. Semaphorin (Sema) 4D, activin-A, and periostin ELISA, LEGENDplex™ Human Bone Metabolism Panel and proteomic analysis for novel biomarker identification were conducted in 71 consecutive samples from NDMM patients. In 25 patients, genomic analysis was performed on sorted clonal plasma cells. NDMM patients had a median age at diagnosis of 65 years and a median follow-up of 2.5 years. Interleukin (IL)-1β and Sema4D levels predicted progression-free survival (PFS), highlighting their role in disease relapse. Proteomic profiling revealed a systemic signature associated with worse prognosis, enriched in complement activation components. Complement C5 significantly affected PFS and time to progression (TTP). IL-1β and C5 predicted PFS independently of the second revision of the International Staging System (R2-ISS) stage, and a similar trend was noted for Sema4D. Myeloma bone disease (MBD) did not significantly affect overall survival, PFS, or TTP, suggesting that contemporary treatments mitigate its impact. Genomic analyses identified variants associated with inferior PFS, including HLA-DRB5 (c.300_306delinsCGGG) and HLA-DQB1 (c.317_319delinsCGG). Sema4D and the IL-1β-complement cascade emerged as key drivers of disease progression, independent of R2-ISS stage, representing potential prognostic and therapeutic targets in NDMM. - Source: PubMed
Publication date: 2026/09/03
Ntanasis-Stathopoulos IoannisNikolaou Panagiota-EfstathiaFilippatos CharalamposMiliotis MariosKostopoulos Ioannis VBakouros PanagiotisMakridakis ManousosLiacos Christine-IvyNikolopoulos KonstantinosLaidou StamatiaChatzidimitriou AnastasiaFrantzi MariaKastritis EfstathiosFotiou DespinaGavriatopoulou MariaVlahou AntoniaHatzigeorgiou Artemis GTsitsilonis OuraniaDimopoulos Meletios AthanasiosTerpos Evangelos - Glioblastoma (GBM) is the most aggressive and malignant primary brain tumor in adults, characterized by rapid growth, diffuse invasion, marked intratumoral heterogeneity, and resistance to conventional therapies. Semaphorin-Plexin signaling, originally identified as a key regulator of axonal guidance during nervous system development, has subsequently emerged as a critical pathway involved in multiple aspects of cancer biology, including tumor proliferation, invasion, angiogenesis, immune modulation, and therapeutic resistance. - Source: PubMed
Publication date: 2026/08/06
Prajapati ShatrudhanSingh Ajay PalTripathi VashnaviYadav Shikha - This study aimed to identify novel circular RNA (circRNA) biomarkers in peripheral blood mononuclear cells (PBMCs) for the diagnosis of ankylosing spondylitis (AS) and to explore their potential pathogenic mechanisms. - Source: PubMed
Publication date: 2026/08/17
Li XinMu CanLiao ShenlingWang ZehaoSu ZhenzhenYang Bin - Macrophage-associated responses at sites of nerve injury are involved in the initiation and persistence of neuropathic pain (NP). Immune semaphorins (SEMAs), including SEMA3A, SEMA3E, SEMA4A, SEMA4D, and SEMA7A, regulate macrophage migration and activation, but their roles in NP remain unclear. This study aimed to identify immune SEMAs associated with NP by analyzing their serum levels and expression in sensory nerve tissues of patients with NP, and to evaluate the potential effects of SEMA-targeted intervention in a mouse model. - Source: PubMed
Publication date: 2026/08/02
Yoshidomi SatoFujii TakayukiHonda HiroyukiKashu Kaoru YoshidaMiyachi YukinoInoue YukaOgata HidenoriYamasaki RyoIwaki ToruIsobe Noriko